Table 12 Sensitivity and specificity for malignant cases of CD56 (total number and percent of cases with positive immunoexpression)
Reference | Benign | Malignant | NG | FA | HA | HCA | FTC | PTC | HCC | FVPTC | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | Sens | Spec | Cut off | TMA | Total | |
Dunđerović (2015) | 79 | 92 % | 122 | 42 % | 30 | 87 % | 27 | 96 % | 12 | 100 % | 10 | 90 % | 15 | 73 % | 87 | 25 % | 20 | 90 % | 40 | 38 % | 58 % | 92 % | 10 % | yes | 201 |
Shahebrahimi K (2013) [64] | 39 | 92 % | 39 | 5 % | 32 | NA | 7 | NA | 39 | 5 % | 5 | NA | 95 % | 92 % | 0 % | no | 78 | ||||||||
Nechifor-Boilă A (2014) [11] | 11 | 64 % | 11 | 18 % | 3 | 33 % | 5 | 60 % | 11 | 18 % | 5 | 20 % | 82 % | 64 % | 10 % | yes | 22 | ||||||||
Abd El Atti RM (2012) [65] | 44 | 93 % | 29 | 17 % | 12 | 92 % | 32 | 88 % | 29 | 17 % | 16 | 19 % | 83 % | 93 % | 10 % | no | 73 | ||||||||
Scarpino S (2007) [61] | 107 | 100 % | 66 | 27 % | 26 | 100 % | 61 | 30 % | 21 | 10 % | 73 % | 100 % | other | no | 173 | ||||||||||
ElDemellawy D (2009) [62] | 100 | 100 % | 75 | 0 % | 2 | NA | 72 | 0 % | 1 | NA | 23 | 0 % | 100 % | 100 % | 10 % | no | 175 | ||||||||
Satoh F (2001) [68] | 11 | 46 % | 39 | 8 % | 11 | 46 % | 10 | 0 % | 14 | 7 % | 92 % | 46 % | 0 % | no | 50 | ||||||||||
Park WY (2009) [63] | 36 | 92 % | 112 | 38 % | 21 | 91 % | 15 | 93 % | 23 | 83 % | 67 | 8 % | 63 % | 92 % | 10 % | no | 148 | ||||||||
Nechifor-Boila A (2013) [69] | NA | 83 % | 204 | 15 % | 204 | 15 % | 90 | 27 % | 85 % | 83 % | 10 % | yes | 204 | ||||||||||||
Mi KS (2011) [66] | 22 | 73 % | 80 | 5 % | 12 | 58 % | 5 | 100 % | 80 | 5 % | 95 % | 73 % | 10 % | no | 102 | ||||||||||
Total | 449 | 777 | 98 | 108 | 44 | 50 | 664 | 21 | 200 | 1226 | |||||||||||||||